Differences in clinicopathologic variables between Borrelia C6 antigen seroreactive and Borrelia C6 seronegative glomerulopathy in dogs.

Permalink
https://escholarship.org/uc/item/38x5402c

Journal
Journal of veterinary internal medicine, 33(5)

ISSN
0891-6640

Authors
Borys, Moria A
Kass, Philip H
Mohr, Frederick C
et al

Publication Date
2019-09-01

DOI
10.1111/jvim.15586

Peer reviewed
Differences in clinicopathologic variables between *Borrelia* C6 antigen seroreactive and *Borrelia* C6 seronegative glomerulopathy in dogs

Moria A. Borys, Philip H. Kass, Frederick C. Mohr, Jane E. Sykes

**Abstract**

**Background:** Rapidly progressive glomerulonephritis has been described in dogs that seroreact to *Borrelia burgdorferi*, but no studies have compared clinicopathologic differences in Lyme-seroreactive dogs with protein-losing nephropathy (PLN) versus dogs with *Borrelia*-seronegative PLN.

**Hypothesis/Objectives:** Dogs with *Borrelia* C6 antigen-seroreactive PLN have distinct clinicopathologic findings when compared to dogs with *Borrelia* seronegative PLN.

**Animals:** Forty dogs with PLN and *Borrelia* C6 antigen seroreactivity and 78 C6-seronegative temporally matched dogs with PLN.

**Methods:** Retrospective prevalence case-control study. Clinical information was retrieved from records of dogs examined at the University of California, Davis, Veterinary Medical Teaching Hospital. Histopathologic findings in renal tissue procured by biopsy or necropsy of dogs with PLN were reviewed.

**Results:** Retrievers and retriever mixes were overrepresented in seroreactive dogs (*P* < .001). Seroreactive dogs were more likely to have thrombocytopenia (*P* < .001), azotemia (*P* = .002), hyperphosphatemia (*P* < .001), anemia (*P* < .001), and neutrophilia (*P* = .003). Hematuria, glucosuria, and pyuria despite negative urine culture were more likely in seroreactive dogs (all *P* ≤ .002). Histopathologic findings were consistent with immune-complex glomerulonephritis in 16 of 16 case dogs and 7 of 23 control dogs (*P* = .006). Prevalence of polyarthritis was not different between groups (*P* = .17).

**Conclusions and Clinical Importance:** C6 seroreactivity in dogs with PLN is associated with a clinicopathologically distinct syndrome when compared with other types of PLN. Early recognition of this syndrome has the potential to improve outcomes through specific aggressive and early treatment.

**Keywords**
glomerulonephritis, Lyme disease, PLN, polyarthritis, pyuria, thrombocytopenia

**Abbreviations:** CI, confidence interval; HLA, histocompatibility leukocyte antigen; ICGN, immune complex glomerulonephritis; MCV, mean corpuscular volume; MGN, membranous glomerulonephritis; PLN, protein-losing nephropathy; UPCR, urine protein:creatinine ratio; VMTH, Veterinary Medical Teaching Hospital.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
1 | INTRODUCTION

The diagnosis of Lyme borreliosis remains challenging for veterinary practitioners presented with dogs with polyarthritis or protein-losing nephropathy (PLN). Similarly, Lyme disease is the most commonly reported tick-borne disease in humans in the United States, but proving a correlation between positive serologic testing and Lyme disease is difficult. The distribution of Lyme disease in the United States is largely determined by its 2 primary tick vectors, *Ixodes scapularis* and *Ixodes pacificus*, and is concentrated in the northeast and upper midwest, and along the Pacific coast. In these areas, up to 40% of healthy dogs may test positive for antibodies to *Borrelia burgdorferi*, but only a small percentage (<10%) of infected dogs are believed to develop clinical signs of disease.

Because organisms are present in very low numbers in connective tissue and are difficult to detect using culture or molecular techniques, diagnosis of acute Lyme borreliosis relies on a combination of characteristic clinical signs (polyarthritis, fever, inappetence), exclusion of other systemic diseases, and seroreactivity to *Borrelia* antigens. The *B. burgdorferi* C6 peptide antigen is a portion of the spirochete VSA surface protein and has been a popular target for serologic assays, because it is only expressed in the host during active infection.

The extended time course of the disease makes it even more difficult for practitioners to associate chronic disorders with *Borrelia* infection. Rheumatologic, neurologic, and cardiac complications have been recognized in humans. Correlations with fibromyalgia, memory impairment, and chronic fatigue also have been proposed in the human medical literature, but the diagnosis of “chronic Lyme disease” remains controversial. All these conditions are poorly documented in dogs with borreliosis. Conversely, a syndrome of severe PLN (“Lyme nephritis”) is believed to occur in 5%-10% of affected dogs, whereas reports of similar renal complications in human patients are rare.

Lyme nephritis is a syndrome of rapidly progressive membranoproliferative glomerulonephritis in *Borrelia*-seroreactive dogs that was first described in 1997. Dogs with Lyme nephritis were significantly younger than dogs with other types of glomerulonephritis, and Golden Retrievers and Labrador Retrievers were overrepresented. Clinicopathologic findings were not described in that study, and to our knowledge, no other studies that compare findings in dogs with suspected Lyme nephritis to findings in dogs with other causes of PLN have been undertaken to date.

We have observed that thrombocytopenia and concurrent polyarthritis are often present in dogs with *Borrelia* C6 antigen-positive PLN but appear to be uncommon in dogs with other types of PLN. Therefore, our goal was to determine whether dogs in northern California with PLN that were seroreactive to the *Borrelia* C6 antigen had distinct clinicopathologic abnormalities that distinguished them from dogs with PLN that were seronegative for the *Borrelia* C6 antigen. We hypothesized that platelet counts would be lower in seroreactive dogs as compared to seronegative dogs, and that the prevalence of polyarthritis would be higher in seroreactive dogs. With this study, we aimed to strengthen the existing evidence that Lyme nephritis is a unique clinical syndrome and to identify clinicopathologic abnormalities that might assist in the early recognition of the disease.

2 | MATERIALS AND METHODS

This study was a retrospective prevalence case-control study. All dogs evaluated at the Veterinary Medical Teaching Hospital (VMTH) at the University of California, Davis, between January 2002 and December 2015, were eligible for inclusion. Electronic medical records were searched for dogs evaluated for PLN that also had vector-borne disease serology performed that included a C6 peptide antibody test (Quantitative C6, SNAP 3DX, SNAP 4DX, and SNAP 4DX Plus, IDEXX Laboratories, Portland, Maine) within 1 month of first being evaluated. For every dog identified with PLN seroreactive for *Borrelia*, 2 temporally associated seronegative control dogs evaluated for PLN were selected for comparison—the dogs seen immediately before and after the seroreactive case (ie, 2 controls for each case). Additional inclusion criteria for all case and control dogs were a urine protein:creatinine ratio (UPCR) >5 or histologically confirmed glomerulonephritis. Dogs were excluded if results of a UPCR performed within 1 month of initial evaluation were not available. Patient age, breed, sex, body weight, rectal temperature at the time of evaluation, clinical signs, and date of onset of illness were recorded. Where performed, results of blood pressure evaluation were recorded and classified as hypertensive (systolic pressure >160 mm Hg) or normotensive. Results of a CBC, serum biochemistry panel, urinalysis, aerobic bacterial urine culture, and serologic testing for other vector-borne diseases, performed within 1 month of initial evaluation, either at the VMTH or at a commercial veterinary diagnostic laboratory, were collected. When the same tests had been performed multiple times, the test performed closest to the time of initial examination for PLN at the VMTH was selected for analysis. Hematologic and biochemical variables were compared to their reference ranges at the time of sample collection (which varied over the study period) to define results as within, above, or below reference ranges. For urinalysis results, microscopic hematuria was defined as ≥10 red blood cells/hpf, and pyuria was defined as ≥5 white blood cells/hpf. Evidence of concurrent polyarthritis was noted; this evidence included either results of synovial fluid analysis documenting neutrophilic inflammation or at least 3 of the following physical examination findings: fever, stiff gait, lameness, joint swelling or effusion, or pain on joint palpation or manipulation. All renal histopathologic findings (obtained by renal biopsy or at necropsy) were recorded. Finally, last known outcome was determined based on medical records and recorded owner communications.

2.1 | Renal histopathology

Available biopsy specimens were classified as consistent or inconsistent with a diagnosis of immune complex glomerulonephritis (ICGN) using criteria similar to those previously published. In brief, specimens submitted to the University of California, Davis Anatomic Pathology service, were fixed in 10% buffered formalin for histologic analysis. Paraffin-embedded tissues then were sectioned at 5 μm thickness and stained routinely with hematoxylin and eosin. Additional sections were prepared for examination by Masson’s trichrome staining, periodic acid Schiff reaction, or Jones methenamine silver method. All microscopic sections were evaluated by a board-certified veterinary anatomic pathologist (F.C.M.). Where biopsy...
specimens had been submitted to the International Veterinary Renal Pathology Service, available histopathologic images were reviewed retrospectively by the same pathologist (F.C.M.). Histologic features suggestive of a diagnosis of ICGN were hypercellularity in the peripheral aspects of glomerular lobules and the mesangium; glomerular basement membrane thickening, duplication, remodeling, spikes, and holes; intracapillary neutrophils; nuclear pyknosis; and mesangial matrix expansion. When available, evidence for the presence of glomerular immune complex deposits also was evaluated by transmission electron microscopy and immunofluorescence microscopy. Dogs with other findings were classified as non-ICGN cases.

2.2 | Statistical analysis

Descriptive statistics were calculated; normally distributed variables were expressed as mean ± standard deviation, and those not normally distributed were expressed as median (range). Categorical data were expressed as frequencies; values with a nonlinear distribution were analyzed categorically. Fisher’s exact test was used to compare categorical variables. Conditional univariate logistic regression was used to estimate matched odds ratios and 95% confidence intervals (CI) relating individual blood variables to being diagnosed as a case versus a control. For histopathologic classification, the odds ratio was estimable using conventional conditional logistic regression, and therefore exact conditional logistic regression was used. A specification link test for single-equation models (link test, Stata, version 11; StataCorp, College Station, Texas) was used to screen for specification errors when using linear quantitative variables. All analyses were performed using commercial statistical software (Stata, version 11; StataCorp).

3 | RESULTS

In all, 40 dogs with *Borrelia* C6-antigen seroreactive PLN were identified for inclusion, along with 78 temporally matched control dogs. Two of the cases had only 1 control dog identified because of insufficient numbers of control dogs evaluated between cases. Differences in categorical variables between cases and controls are shown in Table 1, and continuous variables are shown in Table 2.

Among seroreactive dogs, the most common breeds were Labrador Retrievers (13/40) or Labrador mixes (4/40), Golden Retrievers (4/40) or mixes (1/40), and Australian Shepherds (3/40) or mixes (1/40). Controls similarly were distributed across a variety of breeds, the most common of which were Labrador Retrievers (5/78) or mixes (1/78), American Cocker Spaniels (5/78) or mixes (2/78), Yorkshire Terriers (5/78), and Golden Retrievers (4/78). When Labrador and Golden Retrievers were considered together ("retrievers"; see Table 1), these breeds were overrepresented in the case group. This was true when purebreds were considered alone (P = .001) or when purebreds and mixes were considered together (P < .001).

The median duration of clinical signs before initial examination was 19.0 days for seronegative dogs and 18.5 days for seroreactive dogs (P = .10). Reported clinical signs were inappetence (29/78 controls, 31/40 cases, P < .001), lethargy or weakness (32/78 controls, 25/40 cases, P = .049), vomiting (20/78 controls, 27/40 cases, P < .001), weight loss (14/78 controls, 12/40 cases, P = .18), increased thirst and urination (12/78 controls, 2/40 cases, P = .17), diarrhea (10/78 controls, 3/40 cases, P = .58), joint pain or lameness (6/78 controls, 6/40 cases, P = .37), ascites or peripheral edema (8/78 controls, 0/40 cases, P = .059), and respiratory signs (4/78 controls, 2/40 cases, P = 1.0).

Blood pressure evaluation was performed in 68 of 78 seronegative and 39 of 40 seroreactive dogs. Results were considered consistent with the presence of systemic hypertension in 48 of 68 (70.6%) seronegative dogs and 33 of 39 (84.6%, P = .20) seroreactive dogs.

Low numbers of dogs overall had evidence of polyarthritis at the time of examination (8/40 cases, 7/78 controls, P = .17; Table 1). Physical examination findings consistent with polyarthritis were pain on joint palpation or manipulation (4/7 controls, 3/8 cases), joint swelling or effusion (2/7 controls, 4/8 cases), lameness (1/7 controls, 4/8 cases), stiff gait (2/7 controls, 3/8 cases), fever (1/7 controls, 2/8 cases), spinal pain (1/7 controls), and abnormal stance (1/7 controls). Polyarthritis was confirmed by identification of nonseptic, suppurrative inflammation in synovial fluid specimens in 5 of 8 cases and 6 of 7 controls.

Complete blood count and urinalysis data were available for 39 of 40 cases and all controls, and serum biochemistry panel and UPCR results were available for all cases and controls (Tables 1 and 2). Mean hematocrit was lower (27.0% versus 38.2%, P < .001) and mean corpuscular volume (MCV) was higher (72.7 versus 70.1, P = .005) for cases as compared to controls, although mean MCV remained within reference ranges for both groups. White blood cell counts were nonlinearly distributed, but the proportion of dogs with leukocytosis or leukopenia did not differ between the 2 groups (Table 1). A few dogs in either group had increased numbers of band neutrophils (9/39 cases, 13/78 controls), which typically was mild. Lymphopenia and thrombocytopenia occurred more often in cases than in controls (P = .006 and <.001, respectively), and mean lymphocyte and platelet counts also were lower in case dogs (P = .03 and <.001, respectively). Where present, thrombocytopenia generally was mild to moderate (50 000-150 000 platelets/μL). However, 9 of 26 dogs had platelet counts ≤50 000/μL; 2 of these dogs were controls.

Nearly all dogs in the C6-seroreactive group (38/40) had a serum creatinine concentration above the reference range (>2.2 mg/dL), compared to just over half of the controls (41/78, P = .002; Table 1). Similarly, mean serum urea nitrogen concentration was higher in cases (101.8 mg/dL) as compared to controls (61.7 mg/dL, P < .001; Table 2). Serum phosphorous and potassium concentrations both were higher in cases as compared to controls (P < .001 and .04, respectively), whereas serum albumin concentration was lower in cases (P = .004).

Glucosuria, hematuria, and pyuria were more prevalent in cases than in controls (P < .01 for all; Table 1). Urine protein:creatinine ratios did not differ between the 2 groups. Results of aerobic bacterial urine culture were available for 38 of 40 cases and 74 of 78 controls and were positive in only 1 case dog with growth of >10^5 cfu/mL *Escherichia coli*.

Results of testing for other infectious diseases are shown in Table 3. One case dog seroreacted to *Ehrlichia canis* (1:100) and *Rickettsia rickettsii* (1:25). The other case dog that seroreacted to *R. rickettsii* had a titer of 1:320 with no other identified exposure to co-pathogens (negative for
heartworm antigen, and for antibodies to Ehrlichia, Babesia, and Anaplasma). Six case dogs seroreacted to Anaplasma antigens. Titers were determined for 4 dogs and were 1:640, 1:80, 1:20, and 1:20; none had other known exposures. The single control dog that seroreacted to R. rickettsii (1:160) also seroreacted to Babesia vogeli (titer 1:80). The 4 control dogs that seroreacted to E. canis had titers that ranged from 1:10240 to 1:327680; 2 of these dogs also seroreacted to Anaplasma spp.

The only comorbid disease identified in the case dogs was a hepatic mass of unknown type in 1 dog. Among control dogs, 6 dogs had neoplasia (2 with lymphoma, 2 with mast cell tumors, and 1 each with peripheral nerve sheath tumor, osteochondroma, osteosarcoma, and a complex splenic mass). Three control dogs had central nervous system disease (2 with myelopathies, and 1 with inflammatory brain disease), and 3 control dogs had endocrine disease (1 each with diabetes mellitus, pituitary-dependent hyperadrenocorticism, and inappropriate erythropoietin production). Other diseases in the control dogs included a chronic jejunal intussusception and a perivulvar abscess.

In the 14 days before examination at the VMTH, 31 of 40 case dogs and 48 of 78 control dogs were treated with ≥1 anti-infective agents \((P = .10)\), and 11 of 40 cases and 24 of 78 controls were treated with an anti-inflammatory or immunosuppressive agent \((P = .71; \text{Table 4})\).

Renal biopsy, necropsy, or both was performed in 19 cases and 29 controls. Nine dogs (3 cases and 6 controls) were excluded from assessment of histopathology findings because of missing or non-diagnostic biopsy samples upon review. Renal specimens from all 16 case dogs were classified as consistent with ICGN, as compared to 7 of 23 specimens from controls \((P = .06)\). The remaining control dogs had amyloidosis (6), glomerulosclerosis (4), or a variety of findings that were inconsistent with ICGN (6). If dogs with membranous glomerulonephritis (MGN) were removed from the ICGN category, 15 of 16 cases and 3 of 23 controls were classified as having ICGN \((P = .06, \text{OR}, 7.58; 95\% \text{CI}, 0.90-63.94)\).

The last documented outcome was recorded for all dogs. For cases, 13 of 40 dogs were documented as alive at a median of 72 days after

### TABLE 1
Results of analysis of categorical variables comparing 40 dogs with Borrelia C6-antigen seroreactive PLN and 78 dogs with Borrelia C6-antigen PLN. ICGN, immune-complex glomerulonephritis

| Borrelia C6 seroreactive | Borrelia C6 seronegative | OR    | 95% CI      | \( P \) value |
|--------------------------|--------------------------|-------|-------------|--------------|
| Age ≤8                   | 27/40                    | 44/78 | 1.69        | 0.74-3.90    | .22          |
| Male sex                 | 15/40                    | 42/78 | 0.50        | 0.22-1.12    | .09          |
| Intact                   | 6/40                     | 13/78 | 0.81        | 0.27-2.46    | .72          |
| Rectal temperature ≥102.5 (°F) | 4/40                   | 7/78  | 1.18        | 0.30-4.63    | .81          |
| Retriever                | Purebred                | 17/40 | 9/78        | 5.53        | 2.01-15.22    | .001         |
|                         | Purebred or mix         | 22/40 | 10/78       | 7.22        | 2.70-19.30    | <.001        |
| Hypertension             | 33/39                    | 48/68 | 2.05        | 0.75-6.59    | .20          |
| Polyrthritis             | 8/40                     | 7/78  | 2.55        | 0.71-10.19   | .17          |
| ICGN                     | 16/16                    | 7/23  | 7.30        | 0.96-∞       | .06          |
| CBC                      | Anemia                   | 37/39 | 46/78       | 11.33       | 2.61-49.17    | .001         |
|                         | Thrombocytopenia         | 26/38 | 9/75        | 14.55       | 4.36-48.54    | <.001        |
|                         | Leukocytosis             | 20/39 | 27/78       | 2.00        | 0.90-4.23     | .09          |
|                         | Leukopenia               | 3/39  | 3/78        | 2.00        | 0.40-9.91     | .40          |
|                         | Neutrophilia             | 23/39 | 22/78       | 3.82        | 1.58-9.23     | .003         |
|                         | Lymphopenia              | 18/39 | 17/78       | 3.79        | 1.46-9.87     | .006         |
| Biochemistry             | Creatinine ≥2.2          | 38/40 | 41/78       | 24.67       | 3.30-184.36   | .002         |
|                         | Hyperphosphatemia        | 37/40 | 32/78       | 17.14       | 4.02-72.97    | <.001        |
|                         | Hyperkalemia             | 11/40 | 12/78       | 2.50        | 0.88-7.11     | .09          |
|                         | Hypoalbuminemia          | 38/40 | 63/78       | 4.56        | 0.98-21.35    | .05          |
|                         | Hyperglobulinemia        | 6/40  | 8/77        | 1.55        | 0.51-4.69     | .44          |
| Urinalysis               | Glucosuria               | 19/39 | 10/78       | 9.33        | 2.71-32.14    | <.001        |
|                         | Hematuria                | 19/39 | 16/78       | 4.32        | 1.68-11.11    | .002         |
|                         | Pyuria                   | 12/39 | 0/78        | 33.63       | 5.55-∞       | <.001        |
|                         | Cylindruria              | 22/39 | 33/78       | 1.85        | 0.82-4.14     | .14          |

Abbreviations: OR, odds ratio. CI, confidence interval.
TABLE 2  Results of analysis of continuous variables comparing signalment, hematologic, serum biochemistry analysis, and urinalysis findings in 40 dogs with *Borrelia* C6-antigen seroreactive PLN and 78 dogs with *Borrelia* C6-antigen seronegative PLN

| Variable (unit) | Ref. range | *Borrelia* C6 seroreactive | *Borrelia* C6 seronegative | OR  | 95% CI  | P value |
|----------------|------------|----------------------------|----------------------------|-----|---------|---------|
| **CBC**       |            |                            |                            |     |         |         |
| Age (y)       | NA         | 3.0-11.9                   | 7.0                        | 6.5 | 0.4-18.3 | 7.8     | 7.6     | NL     |
| Body weight (kg) | NA         | 5.9-64.0                   | 24.8                       | 24.7 | 18.3-63.0 | 20.5    | 20.3    | 1.03   | 1.00-1.06 | .09   |
| Rectal temperature (°C) | 99.0-102.5 | 98.0-104.5                 | 101.0                      | 101.0 | 98.3-104.1 | 101.2   | 101.2   | 0.88   | 0.64-1.22 | .45   |
| Duration of clinical signs (days) | NA         | 1-160                      | 34.8                       | 18.5 | 0-498     | 60.7    | 19.0    | 0.99   | 0.99-1.00 | .10   |
| **Biochemistry** |            |                            |                            |     |         |         |
| HCT (%)       | 40-55      | 10.9-47.1                  | 27.1                       | 28.5 | 14.0-62.1 | 38.3    | 37.1    | 0.89   | 0.84-0.95 | <.001 |
| MCV           | 65-75      | 62.5-85.8                  | 72.7                       | 72.7 | 59.2-80.2 | 70.1    | 70.4    | 1.2    | 1.05-1.33 | .005  |
| MCHC          | 33-36      | 31.2-36.4                  | 34.0                       | 33.9 | 27.8-37.8 | 34.4    | 34.6    | 0.80   | 0.59-1.09 | .16   |
| WBC (×1000)   | 60-130     | 4.4-44.1                   | 16.0                       | 13.4 | 4.4-58.8  | 13.2    | 10.2    | NL     |         |       |
| Neutrophils (×1000) | 3.0-10.5 | 3.5-40.5                   | 13.7                       | 11.1 | 2.7-55.7  | 10.3    | 7.6     | NL     |         |       |
| Bands         | Rare       | 0-2921                     | 229.0                      | 0    | 0-1353    | 97.6    | 0       | 1.00   | 1.00-1.00 | .12   |
| Lymphocytes (×100) | 10-40      | 2.2-31.6                   | 11.8                       | 10.1 | 1.6-67.4  | 15.9    | 14.0    | 0.94   | 0.88-1.00 | .03   |
| Platelets (×10,000) | 15-40     | 2.8-54.2                   | 15.1                       | 10.4 | 0.8-84.4  | 35.7    | 31.9    | 0.92   | 0.89-0.96 | <.001 |
| MPV           | 7-13       | 7.4-21.2                   | 13.1                       | 12.7 | 5.8-20.5  | 11.0    | 10.3    | 1.23   | 1.07-1.42 | .005  |
| **Urinalysis** |            |                            |                            |     |         |         |
| Specific gravity | ≥1.025  | 1.010-1.036                 | 1.018                      | 1.017 | 1.006-1.057 | 1.018   | 1.015   | NL     |         |       |
| UPCR          | ≤0.4       | 3.8-27.1                   | 13.8                       | 12.9 | 5.0-64.4  | 14.6    | 11.4    | 0.99   | 0.95-1.03 | .53   |

Abbreviations: BUN, blood urea nitrogen; CI, confidence interval; HCT, hematocrit; MCHC, mean cell hemoglobin concentration; MCV, mean corpuscular volume; MPV, mean platelet volume; NL, nonlinear; OR, odds ratio; UPCR, urine protein:creatinine ratio; WBC, white blood cells.
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.

14 days before initial examination (n = 40) or seronegative (n = 78) to serology, PCR, or both) in dogs with PLN that were seroreactive to C6 antigen had physical examination or arthrocentesis findings that were more likely to be present in dogs suspected to have Lyme nephritis, our findings provide strong support that in dogs with Lyme C6 seroreactive PLN as compared to other types of PLN. When Lyme nephritis was first described in dogs, the existence of an association between seroreactivity and nephritis was questioned because of the high prevalence of subclinical seroreactivity to B. burgdorferi in endemic areas. Although assays that target the Lyme C6 antigen have overcome problems associated with vaccine and nonspecific cross-reactivity that were observed with Borrelia immunofluorescent antibody assays, widespread subclinical infection together with the prolonged (2-5 month) incubation period means that diagnosis of Lyme polyarthritis in dogs still relies upon a combination of positive serology, exclusion of other causes of polyarthritis, and rapid response to treatment with doxycycline. Exclusion of other causes is difficult in dogs with polyarthritis because the primary noninfectious differential diagnosis is idiopathic immune-mediated disease. Diagnosis of Lyme nephritis presents additional challenges, because the time course and underlying cause of PLN typically are difficult to determine even with renal histopathologic examination, and Lyme nephritis usually does not respond to treatment with doxycycline. Currently, diagnosis most often is based on the presence of PLN, exclusion of other causes, and a positive C6 antibody titer, with or without evidence of membranoproliferative glomerulonephritis on histopathology of renal biopsy specimens; no study has consistently detected spirochete DNA or antigen within renal biopsy specimens. In highly endemic areas, the high prevalence of Borrelia in our region is low (1.2%), our patient population was well suited to a case-control study because of the ready availability of a number of temporally matched control dogs.

Although we could not prove that all dogs with antibodies to the C6 antigen had Lyme nephritis, our findings provide strong support that in northern California, dogs with PLN that also have evidence of exposure to Borrelia have a distinct clinical syndrome that separates them from dogs with PLN that have no evidence of exposure to Borrelia. Variables that were more likely to be present in dogs suspected to have Lyme nephritis were thrombocytopenia, azotemia, hyperkalemia, hyperphosphatemia, glucosuria, hematuria, and pyuria. In our study, 20% of dogs that were C6-seroreactive had physical examination or arthrocentesis findings that either suggested or confirmed the presence of polyarthritis, which is similar to the previous report of concurrent lameness or polyarthritis in 26% of dogs with Lyme nephritis. However, most dogs with C6-positive PLN

## Table 3

| Agent                  | Borrelia C6 seroreactive (# positive/# tested) | Borrelia C6 seronegative (# positive/# tested) |
|------------------------|-----------------------------------------------|-----------------------------------------------|
| Babesia spp.           | 6/38                                          | 2/74                                          |
| Babesia spp.           | 2/18                                          | 1/33                                          |
| Leptospira spp. (titer >1:800) | 0/24                                        | 3/26                                          |
| Babesia spp.           | 0/8                                           | 2/21                                          |
| Bartonella spp.        | 0/1                                           | 0/5                                           |
| Coccidioides immitis   | ...                                           | 1/4                                           |

## Table 4

| Medication                          | Borrelia C6 seroreactive (n = 40) | Borrelia C6 seronegative (n = 78) |
|-------------------------------------|----------------------------------|----------------------------------|
| Antibiotics                         |                                  |                                  |
| Penicillins/cephalosporins          | 17                               | 30                               |
| Fluoroquinolones                    | 11                               | 17                               |
| Nitroimidazoles                     | 1                                | 11                               |
| Tetracyclines                       | 18                               | 9                                |
| Macrolides/lincosamides             | 0                                | 3                                |
| Trimethoprim/sulfadiazine           | 0                                | 1                                |
| Antifungals                         | 0                                | 2                                |
| Anti-inflammatory agents            |                                  |                                  |
| Glucocorticoids                     | 5                                | 10                               |
| NSAIDsa                             | 5                                | 15                               |
| Other immunosuppressive drugs       | 2                                | 2                                |

Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs. aIncludes oral and injectable forms; topical ophthalmic formulations excluded.

diagnosis (range, 2-706 days). Of these 13 dogs, 2 had progression of their renal disease, 5 had improved or stable disease, and 6 of 13 had unknown renal status. The remaining 27 dogs died or were euthanized at a median of 7 days after diagnosis (range, 0-965 days); 25 of 27 of these dogs had progressive renal disease. The other 2 dogs had stable renal disease and died of unrelated causes (lymphoma, hepatic mass). Among controls, 40 dogs were alive a median of 64 days after diagnosis (range, 1-1619 days); 9 were known to have progressive renal disease, 10 had improved or stable disease, and 21 had unknown renal status. The remaining 38 dogs died or were euthanized at a median of 42 days after diagnosis (range, 1-2341 days); 36 of 38 had progressive renal disease. One of the other 2 dogs was euthanized for upper airway obstruction, and the other was reported to have died with no further information provided. There was no difference among groups in days to last known outcome (P = .12) or in overall number of dogs experiencing death or euthanasia (P = .08).

4 | DISCUSSION

Our results suggest that a unique set of clinicopathologic abnormalities is present in dogs with Lyme C6 seroreactive PLN as compared to other types of PLN. When Lyme nephritis was first described in dogs, the existence of an association between seroreactivity and nephritis was questioned because of the high prevalence of subclinical seroreactivity to B. burgdorferi in endemic areas. Although assays that target the Lyme C6 antigen have overcome problems associated with vaccine and nonspecific cross-reactivity that were observed with Borrelia immunofluorescent antibody assays, widespread subclinical infection together with the prolonged (2-5 month) incubation period means that diagnosis of Lyme polyarthritis in dogs still relies upon a combination of positive serology, exclusion of other causes of polyarthritis, and rapid response to treatment with doxycycline. Exclusion of other causes is difficult in dogs with polyarthritis because the primary noninfectious differential diagnosis is idiopathic immune-mediated disease. Diagnosis of Lyme nephritis presents additional challenges, because the time course and underlying cause of PLN typically are difficult to determine even with renal histopathologic examination, and Lyme nephritis usually does not respond to treatment with doxycycline. Currently, diagnosis most often is based on the presence of PLN, exclusion of other causes, and a positive C6 antibody titer, with or without evidence of membranoproliferative glomerulonephritis on histopathology of renal biopsy specimens; no study has consistently detected spirochete DNA or antigen within renal biopsy specimens. In highly endemic areas, the high prevalence of Borrelia in our region is low (1.2%), our patient population was well suited to a case-control study because of the ready availability of a number of temporally matched control dogs.

Although we could not prove that all dogs with antibodies to the C6 antigen had Lyme nephritis, our findings provide strong support that in northern California, dogs with PLN that also have evidence of exposure to Borrelia have a distinct clinical syndrome that separates them from dogs with PLN that have no evidence of exposure to Borrelia. Variables that were more likely to be present in dogs suspected to have Lyme nephritis were thrombocytopenia, azotemia, hyperkalemia, hyperphosphatemia, glucosuria, hematuria, and pyuria. In our study, 20% of dogs that were C6-seroreactive had physical examination or arthrocentesis findings that either suggested or confirmed the presence of polyarthritis, which is similar to the previous report of concurrent lameness or polyarthritis in 26% of dogs with Lyme nephritis. However, most dogs with C6-positive PLN
did not have signs of polyarthritis at the time of evaluation. The prevalence of fever was low and not associated with seroreactivity.

Nearly 70% of seroreactive dogs in our study were thrombocytopenic, as previously described. Thrombocytopenia has been reported in association with Lyme disease in humans, and an autoimmune mechanism has been proposed based on the detection of antiplatelet autoantibodies. This finding has been considered controversial because of the possibility of coinfection with *Anaplasma phagocytophilum* (although more recent studies have not shown this finding to be a meaningful confounder), and, in general, thrombocytopenia is considered uncommon to rare in humans with acute Lyme disease. Detectable antibody titers to *Anaplasma, Ehrlichia*, or *Rockettia* antigens (alone or in combination) were present in 7 of 40 case dogs, and the possibility of co-pathogens causing some of the observed clinicopathologic changes cannot be ruled out (although of these 3 agents, only *Ehrlichia* causes chronic, persistent infections that might be associated with PLN, and only 1 case dog seroreacted to *Ehrlichia* with an antibody titer of 1:100). Testing for vector-borne pathogens was not comprehensive in most of the cases, and convalescent serology was performed inconsistently. Therefore, undetected coinfections could not be excluded.

The higher prevalence of azotemia, hyperkalemia, and hyperphosphatemia in the cases compared with the controls is consistent with the previous study that described Borrelia-seropositive PLN as severe and rapidly progressive. This might also explain why higher percentages of case dogs had signs of vomiting, lethargy, weakness, or inappetence reported at the time of initial examination. The presence of azotemia alone cannot be taken to imply direct renal damage given that prerenal azotemia as a consequence of dehydration cannot be excluded. The higher prevalence of glucosuria, hematuria, and pyuria in the cases, however, suggests that more marked tubuloglomerular damage may have been present in cases than in controls. Unexpectedly, pyuria was detected only in the C6-seroreactive dogs, and not in the control dogs, and therefore the presence of pyuria in dogs with PLN may be helpful to support a diagnosis of Lyme nephritis in highly endemic areas. Anemia, neutrophilia, and lymphopenia also were more common in affected dogs in our study.

The largest case study of *Borrelia*-seropositive PLN to date was from the northeastern United States. In that study, only 18 of 49 dogs were tested for antibodies to *Borrelia* (using indirect immunofluorescence, ELISA, or Western blot). Glomerular lesions were suspected to be associated with Lyme disease on the basis of positive serology results in all tested dogs, residence in a Lyme-endemic area, and a previous case report that described similar histopathologic findings. More than half of the dogs in that study were ≤5 years of age. No association with age was seen in our study when the control group was used for comparison, and overall, a lower percentage of dogs in our study (29/118, 25%) were ≤5 years of age. Labrador and Golden Retrievers comprised over 40% of the dogs in that study were seropositive as a consequence of previous subclinical exposure or infection with subsequent development of PLN from unrelated causes. However, the overall prevalence of seroreactivity in the geographic region in which the majority of the dogs in our study resided is low, and our experience is that, when tested, dogs seen at our hospital with clinical abnormalities that are not consistent with those described for Lyme disease rarely seroreact to *Borrelia* C6 antigen. The C6 assay is sensitive (84.2%-96.7%) and specific (96.1%-98.8%) as compared to Western blotting. Although false-positive test results are possible in low-prevalence populations, the selection of a population of at-risk dogs (i.e., those with evidence of PLN) likely increased the positive
predictive value of *Borrelia* testing. Lastly, for the diagnosis of PLN, an arbitrary value of UPCR >5 was selected; occasionally tubular disease alone may cause UP CRs of this magnitude, and biopsy confirmation of glomerulonephritis was not obtained in some cases. However, this cut-off value is similar to criteria that have been used in other studies and was intentionally selected to be substantially higher than American College of Veterinary Internal Medicine guidelines (describing glomerular proteinuria as persistent UPCR ≥2.0\(^{41}\)) in order to decrease the chance of including dogs with tubular proteinuria. A single seropositive dog with a positive urine culture, which may have confounded UPCR results, was also included, but UPCR for that dog remained increased (>15) after treatment of the infection and subsequent negative urine culture results.

In conclusion, we have provided additional evidence that Lyme nephritis has clinical features that distinguish it from other causes of PLN. Factors that may add weight to a diagnosis of Lyme nephritis in seroreactive dogs with PLNI include disease in a retriever or retriever mix; biochemical evidence of azotemia, hyperkalemia, and hyperphosphatemia; findings of thrombocytopenia, anemia, or neutrophilia on CBC, and the presence of hematuria, glucosuria, and pyuria despite negative urine culture. Concurrent polyarthritis was not found to be a distinguishing characteristic in our study, although subclinical polyarthritis may have been present in some dogs from each group but not recognized. Until further evidence is available to guide appropriate treatment, given the recognized poor prognosis associated with this syndrome, combinations of these identified features in C6-seropositive dogs should prompt aggressive treatment with both doxycycline and immunosuppressive drug treatment.\(^{22,42}\)

**ACKNOWLEDGMENTS**

This study was presented orally as an abstract at the 2018 ACVIM Forum, Seattle, WA. The authors recognize the International Veterinary Renal Pathology Service (IVRPS) and the contributions of G.E. Lees, R.E. Cianciolo, B.R. Berridge, F.J. Clubb, and C.A. Brown in the evaluation of the pathologic lesions and diagnoses of a subset of the renal biopsy specimens used in the analysis of this work.

**CONFLICT OF INTEREST DECLARATION**

Jane Sykes serves as Associate Editor for the *Journal of Veterinary Internal Medicine*. She was not involved in review of this manuscript.

**OFF-LABEL ANTIMICROBIAL DECLARATION**

Authors declare no off-label use of antimicrobials.

**INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION**

Authors declare no IACUC or other approval was needed.

**HUMAN ETHICS APPROVAL DECLARATION**

Authors declare human ethics approval was not needed for this study.

**ORCID**

Maria A. Borys https://orcid.org/0000-0001-5058-1243

**REFERENCES**

1. Adams DA, Thomas KR, Jajosky RA, et al. Summary of notifiable infectious diseases and conditions—United States, 2014. *MMWR Morb Mortal Wkly Rep*. 2016;65:1-152.
2. Carrade D, Foley J, Sullivan M, Foley CW, Sykes JE. Spatial distribution of seroprevalence for *Anaplasma phagocytophylum*, *Borrelia burgdorferi*, *Ehrlichia canis*, and *Dirofilaria immitis* in dogs in Washington, Oregon, and California. *Vet Clin Pathol*. 2011;40:293-302.
3. Johnson JL, Ginsberg HS, Zhioua E, et al. Passive tick surveillance, dog seropositivity, and incidence of human Lyme disease. *Vector Borne Zoonotic Dis*. 2004;4:137-142.
4. Guerra MA, Walker ED, Kitron U. Canine surveillance system for Lyme borreliosis in Wisconsin and northern Illinois: geographic distribution and risk factor analysis. *Am J Trop Med Hyg*. 2001;65:546-552.
5. Levy SA, Magnarelli LA. Relationship between development of antibodies to *Borrelia burgdorferi* in dogs. *J Am Vet Med Assoc*. 1992;200:344-347.
6. Scorpio DG, Wachtman LM, Tunin RS, Barat NC, Gauy JW, Dumler JS. Retrospective clinical and molecular analysis of conditioned laboratory dogs (*Canis familiaris*) with serologic reactions to *Ehrlichia canis*, *Borrelia burgdorferi*, and *Rickettsia rickettsii*. *J Am Assoc Lab Anim Sci*. 2008;47:23-28.
7. Zhang JR, Hardham AM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. *Cell*. 1997;89:275-285.
8. Koedel U, Fingerle V, Pfister HW. Lyme neuroborreliosis-epidemiology, diagnosis and management. *Nat Rev Neurol*. 2015;11:446-456.
9. Halperin JJ. Chronic Lyme disease: misconceptions and challenges for patient management. *Infect Drug Resist*. 2015;8:119-128.
10. Muehlenbachs A, Bollweg BC, Schulz TJ, et al. Cardiac tropism of *Borrelia burgdorferi*: an autopsy study of sudden cardiac death associated with Lyme carditis. *Am J Pathol*. 2016;186:1195-1205.
11. Aucoot JN. Posttreatment Lyme disease syndrome. *Infect Dis Clin North Am*. 2015;29:309-323.
12. Lantos PM. Chronic Lyme disease. *Infect Dis Clin North Am*. 2015;29:325-340.
13. Levy SA, Duray PH. Complete heart block in a dog seropositive for *Borrelia burgdorferi*. Similarity to human Lyme carditis. *J Vet Intern Med*. 1988;2:138-144.
14. Chang YF, Novosel V, Chang CF, et al. Experimental induction of chronic borreliosis in adult dogs exposed to *Borrelia burgdorferi*-infected ticks and treated with dexamethasone. *Am J Vet Res*. 2001;62:1104-1112.
15. Detmer SE, Boulijah M, Hayden DW, Schefers JM, Armien A, Wünschmann A. Fatal pyogranulomatous myocarditis in 10 boxer puppies. *J Vet Diagn Invest*. 2016;28:144-149.
16. Rolla D, Conti N, Ansaldi F, et al. Post-infectious glomerulonephritis presenting as acute renal failure in a patient with Lyme disease. *J Renal Inj Prev*. 2014;3:17-20.
17. Kirmizis D, Efstratiadis G, Economidou D, Diza-Mataftsi E, Leontsini M, Memmos D. MPGN secondary to Lyme disease. *Am J Kidney Dis*. 2004;43:544-551.
18. Dambach DM, Smith CA, Lewis RM, Van Winkle TJ. Morphologic, immunohistochemical, and ultrastructural characterization of a
distinctive renal lesion in dogs putatively associated with Borrelia burgdorferi infection: 49 cases (1987-1992). Vet Pathol. 1997;34:85-96.

19. Mehrkens LR, Mohr FC, Sykes JE. Clinicopathologic and histopathologic renal abnormalities in dogs with coccidioidomycosis. J Vet Intern Med. 2016;30:1667-1671.

20. Hutton TA, Goldstein RE, Njaa BL, Atwater DZ, Chang YF, Simpson KW. Search for Borrelia burgdorferi in kidneys of dogs with suspected “ Lyme nephritis” . J Vet Intern Med. 2008;22:860-865.

21. Chou J, Wünschmann A, Hodzeic E, Borjesson DL. Detection of Borrelia burgdorferi DNA in tissues from dogs with presumptive Lyme borreliosis. J Am Vet Med Assoc. 2006;229:1260-1265.

22. Goldstein RE, Broida C, Fernández-Del Palacio MJ, et al. Consensus recommendations for treatment of dogs for serology positive glomerular disease. J Vet Intern Med. 2013;27(Suppl 1):S60-S66.

23. Stefan N, Elsner S, Schnait D, Wernet D, Stumvoll M. Autoimmune thrombocytopenia associated with Borrelia burgdorferi. Clin Infect Dis. 1999:28:927.

24. Nadolman RB, Nowakowski J, Horowitz HW, Strie F, Wormser GP. Thrombocytopenia and Borrelia burgdorferi: an association remains unproven. Clin Infect Dis. 1999;29:1603-1605.

25. Strie F, Bogović P, Cimperman J, et al. Are patients with erythema migrans who have leukopenia and/or thrombocytopenia coinfected with Anaplasma phagocytophilum or tick-borne encephalitis virus? PLoS One. 2014;9:e103188.

26. Wormser GP, Aguero-Rosenfeld ME, Cox ME, et al. Differences and similarities between culture-confirmed human granulocytic anaplasmosis and early Lyme disease. J Clin Microbiol. 2013;51:954-958.

27. Grauer GF, Burgess EC, Cooley AJ, Hagee JH. Renal lesions associated with Borrelia burgdorferi infection in a dog. J Am Vet Med Assoc. 1988;193:237-239.

28. Goldstein RE, Cordner AP, Sandler JL, Bellohusen BA, Erb HN. Microalbuminuria and comparison of serologic testing for exposure to Borrelia burgdorferi in nonclinical Labrador and Golden retrievers. J Vet Diagn Invest. 2007;19:294-297.

29. Kalish RA, Leong JM, Steere AC. Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi. Infect Immun. 1993;61:2774-2779.

30. Steere AC, Dwyer E, Winchester R. Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles. N Engl J Med. 1990;323:219-223.

31. Steere AC, Klitz W, Drouin EE, et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR4 molecules that bind a Borrelia burgdorferi peptide. J Exp Med. 2006;203:961-971.

32. Ilipoulou BP, Guerou-de-Arellano M, Huber BT. HLA-DR alleles determine responsiveness to Borrelia burgdorferi antigens in a mouse model of self-perpetuating arthritis. Arthritis Rheum. 2009;60:3831-3840.

33. Seward RJ, Drouin EE, Steere AC, Costello CE. Peptides presented by HLA-DR molecules in synovia of patients with rheumatoid arthritis and antibiotic-refractory Lyme arthritis. Mol Cell Proteomics. 2011;10:M110.002477.

34. Wang Q, Drouin EE, Yao C, et al. Immunogenic HLA-DR-presented self-peptides identified directly from clinical samples of synovial tissue, synovial fluid, or peripheral blood in patients with rheumatoid arthritis or Lyme arthritis. J Proteome Res. 2017;16:122-136.

35. Drouin EE, Seward RJ, Strie K, et al. A novel human autoantigen, endothelial cell growth factor, is a target of T and B cell responses in patients with Lyme disease. Arthritis Rheum. 2013;65:186-196.

36. Crowley JT, Drouin EE, Pinta A, et al. A highly expressed human protein, apolipoprotein B-100, serves as an autoantigen in a subgroup of patients with Lyme disease. J Infect Dis. 2015;212:1841-1850.

37. Crowley JT, Strie K, Drouin EE, et al. Matrix metalloproteinase-10 is a target of T and B cell responses that correlate with synovial pathology in patients with antibiotic-refractory Lyme arthritis. J Autoimmun. 2016;69:24-37.

38. Levy S, O’Connor TP, Hanscom JL, Shields P. Utility of an in-office C6 ELISA test kit for determination of infection status. Vet Ther. 2002;3:308-315.

39. Barth C, Straubinger RK, Krupka I, Müller E, Sauter-Louis C, Hartmann K. Comparison of different diagnostic assays for the detection of Borrelia burgdorferi-specific antibodies in dogs. Vet Clin Pathol. 2014;43:496-504.

40. Stillman BA, Monn M, Liu J, et al. Performance of a commercially available in-clinic ELISA for detection of antibodies against Anaplasma phagocytophilum, Anaplasma platys, Borrelia burgdorferi, Ehrlichia canis, and Ehrlichia ewingii and Dirofilaria immitis antigen in dogs. J Am Vet Med Assoc. 2014;245:80-86.

41. Lees GE, Brown SA, Elliott J, Grauer GE, Vaden SL, American College of Veterinary Internal Medicine. Assessment and management of proteinuria in dogs and cats: 2004 ACVIM forum consensus statement (small animal). J Vet Intern Med. 2005;19:377-385.

42. Littman MP, Gerber B, Goldstein RE, Labato MA, Lappin MR, Moore GE. ACVIM consensus update on Lyme borreliosis in dogs and cats. J Vet Intern Med. 2018;32:887-903.